BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Talks.cam//talks.cam.ac.uk// X-WR-CALNAME:Talks.cam BEGIN:VEVENT SUMMARY:Cambridge MedAI Seminar - January 2025 - Greta Markert and Dr Kare n Sayal DTSTART:20250129T114500Z DTEND:20250129T130000Z UID:TALK226114@talks.cam.ac.uk CONTACT:Hannah Clayton DESCRIPTION:Sign up for this seminar on Eventbrite: https://www.eventbrite .co.uk/e/cambridge-medai-seminar-series-tickets-1142276031359?aff=oddtdtcr eator\n\nJoin us for the *Cambridge AI in Medicine Seminar Series*\, hoste d by the *Cancer Research UK Cambridge Centre* and the *Department of Radi ology at Addenbrooke's*. This series brings together leading experts to ex plore cutting-edge AI applications in healthcare—from disease diagnosis to drug discovery. It's a unique opportunity for researchers\, practitione rs\, and students to stay at the forefront of AI innovations and engage in discussions shaping the future of AI in healthcare.\n\nThis month's semin ar will be held on *Wednesday 29 January 2025\, 12-1pm at the Jeffrey Chea h Biomedical Centre (Main Lecture Theatre)\, University of Cambridge* and *streamed online via Zoom*. A light lunch from Aromi will be served from 1 1:45. The event will feature the following talks:\n\n\n\n*_AI in Histopath ology: Practical Lessons from an Unconventional Case Study_ - Greta Marker t\, PhD student\, Cancer Research UK Cambridge Institute/University of Cam bridge*\n\nGreta studied both Chemistry and Pharmaceutical Sciences at ETH Zurich with a strong focus on computational approaches. During her master ’s thesis at IBM Research\, she explored AI for drug discovery\, which s parked her passion for artificial intelligence. Currently\, she is in the final year of her PhD at the Cancer Institute in Cambridge\, working under Prof. Florian Markowetz and Prof. Rebecca Fitzgerald at the Early Cancer Institute\, working on AI in histopathology. Before starting her PhD\, she worked in management consulting and in the patents department of Roche.\n \n*Abstract*: Artificial intelligence in histopathology has predominantly focused on traditional biopsy samples. My research\, however\, applies AI to whole slide images derived from the capsule sponge\, a minimally invasi ve alternative to endoscopy. The capsule sponge collects random cellular m aterial along the esophagus\, presenting distinct analytical challenges. O ur work involves three stains—H&E for quality control and atypical featu res\, TFF3 for detecting Barrett’s esophagus\, and TP53 for tumor progre ssion assessment—each addressing specific diagnostic questions. By integ rating these stains and analyzing corresponding cellular structures\, we e nhance risk stratification and advance early detection of esophageal cance r. This presentation will outline the novel computational strategies devel oped to tackle this unique and complex application.\n\n\n\n*_Next generati on technology for next generation trials_ - Dr Karen Sayal\, Senior Direct or in AI-driven Clinical Development and Clinical Translation at Recursion Pharmaceuticals & Honorary Consultant in Clinical Oncology\, Cambridge Un iversity NHS Foundation Trust*\n\nDr Karen Sayal is a Senior Director in A I-driven Clinical Development and Clinical Translation at Recursion Pharma ceuticals where she is focused on implementing high-throughput industrial scale clinical trials. She is also a honorary consultant in Clinical Oncol ogy at Cambridge University NHS Foundation Trust.\n\nDr Sayal completed me dical school at the University of Cambridge (Gonville and Caius college). Her specialist clinical training spanned across Cambridge and Oxford\, whi ch included being the first NIHR-funded academic clinical fellow in Clinic al Oncology at Oxford. She completed a CRUK-funded DPhil in advanced seque ncing technologies and machine learning at the University of Oxford. Prior to joining Recursion\, Dr Sayal was a Fellow in Deep Learning in the AI/M L division of GSK. She is the first and only clinician to have embarked on the GSK AI fellowship scheme where she worked across technical AI researc h\, clinical trial design\, clinical data networks and AI regulation.\n\n* Abstract*: Clinical trials are being transformed through an evolving suite of innovative AI-driven technologies combined with data-driven insights o n the clinical and biological profile of disease. Such transformation is a reflection of a more fundamental shift where technology\, drug developmen t and patient care are coming together to redefine how we view and manage perturbed states of human physiology. In the next Cambridge MedAI seminar\ , Dr Karen Sayal will give an overview of the current landscape of trial-r eady AI tools. She will also spotlight emerging growth areas for clinical AI technologies\, and offer critical insights into the challenges we must collectively address to ensure AI innovation is deployed in a safe and mea ningful way for patients.\n\n\nThis is a hybrid event so you can also join via Zoom:\n\nhttps://zoom.us/j/99050467573?pwd=UE5OdFdTSFdZeUtIcU1DbXpmdl NGZz09\n\nMeeting ID: 990 5046 7573 and Passcode: 617729\n\n\n\nWe look fo rward to your participation! If you are interested in getting involved and presenting your work\, please email Ines Machado at im549@cam.ac.uk\n\n\n \nFor more information about this seminar series\, see: https://www.integr atedcancermedicine.org/research/cambridge-medai-seminar-series/ LOCATION:Jeffrey Cheah Biomedical Centre (Main Lecture Theatre)\, Universi ty of Cambridge END:VEVENT END:VCALENDAR